In this series of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss how to leverage immunotherapy in gynecologic cancers.
EP. 1: Immunotherapy and You: How Has Immunotherapy Changed Gynecologic Cancer Practice?
October 26th 2022In this first episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, explain how immunotherapy has changed practice for the treatment of patients with gynecologic cancers.
EP. 2: Immunotherapy and You: Gynecologic Treatment Efficacy From a Patient’s Perspective
November 2nd 2022In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss the safety and efficacy of immunotherapy vs standard chemotherapy in patients with gynecologic cancers.
EP. 5: Immunotherapy and You: Understanding the PD-L1 Blockade
November 23rd 2022In this fifth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss PD-1 blockade, potential biomarkers of response to treatment with immunotherapy, and the potential for these agents in the neoadjuvant setting.
EP. 6: Immunotherapy and You: Checkpoint Inhibitors in Gynecologic Cancers
November 30th 2022In this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.
EP. 7: FDA Approvals of Immunotherapy in Gynecology Oncology
December 7th 2022In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.